DGX

T2S&P 500Health Care (XLV)Momentum (MTUM)Value (IWD)Low Volatility (SPLV)

Quest Diagnostics Incorporated

Next est. report 2027-02-09 · BMO

Data Owners '25: Healthcare, Claims & Clinical Data Diagnostics '26: Broad Diagnostic Platforms & Labs MedTech Long '24: Lab Research & Trials MedTech Long '26: Diagnostics & Early Detection

Loading…

Loading chart…

Overview

Quest Diagnostics provides diagnostic testing, information, and services globally, from routine to advanced clinical and anatomic pathology. Serving patients, c

Quest Diagnostics provides diagnostic testing, information, and services globally, from routine to advanced clinical and anatomic pathology. Serving patients, clinicians, hospitals, and health plans, it reported 10% revenue growth in Q3 2026. The company leverages AI and automation for efficiency, offers innovative diagnostics like Alzheimer's tests, and expanded its consumer health channel with Apple Health integration, driving strong growth.

Key Inputs And Sourcing

1. Labor (Wages)

Matched (medium)lab_wages_ahe · access=api

labor · United States · 30-40%

Source Wage increases mentioned as impacting operating income.

Confidence: low

2. Reagents and Consumables

Not in registry

component · Global · 15-25%

Source Essential for diagnostic testing, implied by mentions of specific tests (e.g., Roche p-tau217 test, Onclarity self-collection kit) and general lab operations.

Confidence: high

3. Logistics and Fuel

Not in registry

logistics · gasoline · United States · ~2-4% (fuel portion)

Source Fuel costs explicitly mentioned as elevated, impacting operating margins. Logistics is critical for specimen transport across a national network.

Confidence: high

4. Diagnostic Equipment and Automation

Not in registry

component · Global · unknown (capital expenditure, depreciation in COGS)

Source Significant investments in automation and AI, including automated aliquoting solutions and Hologic Genius digital diagnostic system. Capital expenditures are approximately $550 million.

Confidence: high

5. IT and Software (Project Nova, AI)

Not in registry

other · Global · unknown (significant investment, mostly OpEx)

Source Project Nova is a multi-year initiative with significant expenses, and AI is a major driver of productivity.

Confidence: high

6. Specimen Collection Kits and Packaging

Not in registry

packaging · Global · 5-10%

Source Mention of Onclarity self-collection kit and general need for blood draw supplies at Patient Service Centers.

Confidence: medium

7. Utilities (Electricity, Water)

Not in registryaccess=api

energy · electricity · Local · 2-5%

Source Labs require significant electricity for equipment and water for processes, including dialysis water testing.

Confidence: medium

8. Rent and Leases (Labs, PSCs)

Not in registry

other · United States · unknown (OpEx, not direct COGS)

Source Extensive network of laboratories and patient service centers.

Confidence: medium

9. Medical Waste Disposal

Not in registry

other · Local · <1%

Source Standard operational cost for medical diagnostic labs due to biohazardous materials.

Confidence: low

Industry Publications

[]

Economic Data Watch

1. FRED — Personal Consumption Expenditures

Matchedfred · access=api · map_only

Metric/field DHLCRC1Q027SBEA

Cadence monthly

Why it matters Indicates overall spending on healthcare services, which directly impacts Quest Diagnostics' addressable market and revenue potential.

Signal to watch Increasing trend signals a growing market for diagnostic services.

Confidence: high

2. FRED — Employment Cost Index

Matchedfred · access=api · map_only

Metric/field ECIWAG

Cadence monthly

Why it matters Reflects changes in labor costs for private industry workers, directly impacting Quest Diagnostics' operating expenses, especially given their large workforce.

Signal to watch Slowing growth or decline indicates potential relief on wage inflation pressures.

Confidence: high

3. FRED — Crude Oil Prices

Matchedfred · access=api · map_only

Metric/field DCOILWTICO

Cadence monthly

Why it matters Fuel costs are explicitly mentioned as an operating expense for Quest Diagnostics, impacting their logistics and transportation network.

Signal to watch Decreasing prices suggest a reduction in operational cost headwinds.

Confidence: high

4. FRED — Real Personal Consumption Expenditures

Matchedfred · access=api · map_only

Metric/field PCESVC96

Cadence monthly

Why it matters A broad indicator of consumer spending on services, which includes healthcare and the consumer health channel, reflecting overall economic health and discretionary spending capacity.

Signal to watch Sustained growth indicates robust consumer demand for services, including diagnostic testing.

Confidence: high

5. FRED — Consumer Price Index

Matchedfred · access=api · map_only

Metric/field CPIAUCSL

Cadence monthly

Why it matters General inflation impacts Quest Diagnostics' overall operating costs, including supplies, utilities, and other non-labor expenses.

Signal to watch Moderating or declining inflation rates could alleviate cost pressures.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

Not in registry

Metric/field Study Status, Biomarkers, Sponsor

Cadence daily

Why it matters Tracks the development and validation of new diagnostic tests, particularly in key growth areas like Alzheimer's and oncology, which can expand Quest Diagnostics' test portfolio and market opportunities.

Signal to watch New trials, positive study results, or Quest Diagnostics' involvement in trials indicate future growth drivers.

Confidence: high

2. FDA — Medical Device 510(k) Clearances and Premarket Approvals (PMA)

Not in registry

Metric/field Device Name, Applicant, Product Code, Decision Date

Cadence monthly

Why it matters Indicates new diagnostic devices and tests receiving regulatory approval, which can represent new market opportunities or competitive threats for Quest Diagnostics.

Signal to watch Increased approvals for blood-based diagnostics in oncology, neurology, or cardiometabolic areas are bullish.

Confidence: high

3. SEC EDGAR — Company Filings

Not in registry

Metric/field 8-K Filings

Cadence event_driven

Why it matters Provides timely notification of material events affecting Quest Diagnostics, such as acquisitions, divestitures, significant contracts, cybersecurity incidents, or changes in financial guidance.

Signal to watch Filings related to M&A, strategic partnerships, or significant operational changes are key.

Confidence: high

4. Google Trends — Search Interest

Not in registry

Metric/field Search term volume for 'Alzheimer's blood test' AND 'cancer screening blood test'

Cadence weekly

Why it matters Reflects public and physician interest and awareness in key diagnostic technologies, signaling potential market adoption and demand for Quest Diagnostics' advanced tests.

Signal to watch Increasing search volume indicates growing market interest and potential for increased test orders.

Confidence: medium

5. USPTO PatentsView — Patent Grants and Applications

Not in registry

Metric/field Assignee: Quest Diagnostics, CPC Class: G16H (Health informatics) OR G01N (Measuring; Testing)

Cadence quarterly

Why it matters Indicates Quest Diagnostics' and competitors' innovation in diagnostic technologies, AI, and automation, which are critical for future growth and operational efficiency.

Signal to watch New patent grants for Quest Diagnostics in AI-driven diagnostics or novel biomarkers are bullish.

Confidence: high

Paid Alt Data Watch

1. IQVIA / Symphony Health — Medical Claims Data

Matchediqvia_medical_claims · access=file · map_only

Metric/field CPT code utilization for molecular diagnostic tests (e.g., specific codes for liquid biopsy, MRD, MCED, Alzheimer's biomarkers)

Cadence monthly

Why it matters Provides granular, independent data on actual test utilization, market share, and reimbursement trends for advanced diagnostic tests, directly impacting Quest Diagnostics' revenue.

Signal to watch Increasing utilization of advanced diagnostic CPT codes, especially for tests offered by Quest Diagnostics, indicates market adoption.

Confidence: high

2. Definitive Healthcare — PhysicianView / ClaimsMx

Not in registry

Metric/field Physician Ordering Analytics: HCPCS code and Order Entity for lab tests

Cadence monthly

Why it matters Offers insights into physician ordering patterns for lab tests, helping to understand market share, competitive dynamics, and the effectiveness of Quest Diagnostics' sales and marketing efforts.

Signal to watch Increased ordering volume by physicians for Quest Diagnostics' tests or in key therapeutic areas is bullish.

Confidence: high

3. Truveta — EHR Data

Matched (medium)truveta_ehr_clinical_records · access=file · map_only

Metric/field Lab Order Volume by Test Type and Diagnosis, Patient Demographics

Cadence daily

Why it matters Provides real-world evidence of diagnostic test utilization, patient populations, and clinical outcomes, which can inform Quest Diagnostics' strategy and demonstrate market impact.

Signal to watch Growth in lab orders for advanced diagnostics among diverse patient populations indicates strong market penetration.

Confidence: high

4. Consumer Edge — Healthcare Claims Data (Phoenix/Hydrus)

Matchedconsumer_edge_medical_claims · access=file · map_only

Metric/field Medical Procedures Volume, Pharmacy Dispensing Volume (for relevant conditions)

Cadence monthly

Why it matters Offers a broad view of healthcare activity and consumer spending on medical services, providing context for Quest Diagnostics' overall market performance and consumer health channel growth.

Signal to watch Increasing volumes in relevant medical procedures or pharmacy categories suggest underlying demand for diagnostic support.

Confidence: high

5. LegiScan — U.S. Legislative Database

Matched (medium)legiscan_legislation_bills · access=file · map_only

Metric/field Bill Status, Vote Records, Sponsor Activity for 'RESULTS Act' OR 'PAMA reform'

Cadence daily

Why it matters Directly tracks legislative efforts to reform PAMA and influence Medicare reimbursement rates, which is a significant financial factor for Quest Diagnostics.

Signal to watch Progress towards the passage of the RESULTS Act or other PAMA reforms is a bullish signal for reimbursement stability.

Confidence: high

Search Keywords Brand Product

questhealth.com
AD-Detect
Haystack MRD
Lp(a) test
ApoB test
Roche p-tau217 test
Onclarity self-collection kit
Apple Health app integration
Quanum Lab Services Manager
diagnostic testing
clinical laboratories
advanced diagnostics
consumer health
AI in healthcare
automation in labs
kidney diagnostics
Alzheimer's disease testing
cervical cancer screening
preventative health
wellness testing
cybersecurity incident

Search Keywords Event Phrases

Quest Diagnostics earnings
PAMA rate cuts
RESULTS Act vote
Apple Health app launch
cybersecurity breach

Search Keywords Policy Regulatory

Protecting Access to Medicare Act PAMA
RESULTS Act
Clinical Laboratory Fee Schedule CLFS

What They Do (Plain English & Analogies): Quest Diagnostics is like a central lab for doctors and hospitals. When you go to the doctor and they need to figure out what's going on inside your body, they often take samples like blood or urine. Quest Diagnostics is one of the biggest companies that processes these samples, running a huge variety of tests, from simple checks like cholesterol to highly specialized tests for complex diseases such as Alzheimer's or various cancers. They also help hospitals manage their own labs, provide services directly to individuals who want to monitor their own health, and offer services to the life insurance industry. Their main goal is to connect people and healthcare providers with innovative testing and useful information to help everyone be more proactive and personal about their health. They are increasingly using smart technologies like AI and automation to make testing simpler and smarter, enhancing quality, productivity, and efficiency for patients and their core clinical customers.
Very Brief History: Quest Diagnostics Incorporated was founded in 1967 as Metropolitan Pathology Laboratory, Inc. in New York City. After several name changes and acquisitions, it became an independent company in 1996, spinning off from Corning. Headquartered in Secaucus, New Jersey, Quest Diagnostics has since grown into a premier global provider of diagnostic testing and information services.
"Street Stereotype": Quest Diagnostics is generally perceived by investors and analysts as a stable, large-cap leader in the diagnostics and early detection sector. It's seen as a vital part of healthcare infrastructure, especially for deploying advanced blood-based tests for conditions like Alzheimer's and cancer. The 'street' views it as a company benefiting from technological advancements in genomics and AI, and increasing demand for proactive health monitoring, despite facing ongoing reimbursement pressures (like PAMA) and competition. The strong Q3 performance and raised guidance reinforce a bullish outlook on its ability to execute its strategy and generate shareholder value.
Subsidiaries On Linked In*: {"subsidiaries":[{"name":"AmeriPath","linkedin_hint":"ameripath","notes":"Provides diagnostic solutions, advanced technology, and pathology testing."產業: 28},{"name":"Dermpath Diagnostics","linkedin_hint":"dermpath-diagnostics","notes":"Focuses on accurate, clear, and prompt diagnoses of skin conditions."},{"name":"ExamOne","linkedin_hint":"examone","notes":"Offers risk assessment services for the life insurance industry."},{"name":"Quanum","linkedin_hint":"","notes":"Provides healthcare information technology solutions, including Lab Services Manager, eLabs, EHR, and ePrescribing."},{"name":"Quest Cardiometabolic Center of Excellence at Cleveland HeartLab","linkedin_hint":"","notes":"National center of excellence focused on identifying hidden heart disease risk."},{"name":"ReproSource","linkedin_hint":"","notes":"Focuses exclusively on reproductive health testing."},{"name":"Blueprint Genetics","linkedin_hint":"blueprint-genetics","notes":"Provides high-quality genetic testing across 15 medical specialties."產業: 28},{"name":"Athena Diagnostics","linkedin_hint":"","notes":"Runs highly comprehensive diagnostic testing for neurological, endocrine, and renal conditions."產業: 28},{"name":"Labtech Diagnostics","linkedin_hint":"","notes":"Provides reliable, timely, accurate, and innovative diagnostic services."}]}
Customer Sectors & Example Clients: Quest Diagnostics serves a broad range of customer sectors including patients, clinicians (physicians), hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Specific top clients and collaborators mentioned include Corewell Health (a leading health system in Michigan, for Co-Lab Solutions), Fresenius Medical Care (for comprehensive kidney testing and dialysis-related lab services), and a leading health system in the Northeastern U.S. (for an upcoming outreach acquisition).
New Customers / Segments They'Re Targeting: Quest Diagnostics is actively targeting the growing nephrology call point, having been named the primary national lab provider for pre-dialysis chronic kidney disease testing for a kidney care organization. They are also expanding their consumer health channel by enabling iPhone and iPad users to order labs directly from the Apple Health app, aiming to serve individuals interested in preventative health and wellness. Additionally, they are pursuing new Co-Lab collaborations and outreach acquisitions with health systems, as evidenced by the definitive agreement to acquire select outreach assets from a longtime Co-Lab customer in the Northeastern U.S.
Sales Geographies And Expansion Plans: Quest Diagnostics primarily operates in the United States, serving one in three adult Americans and half the physicians and hospitals, with a national network of laboratories and approximately 2,000 patient service centers. Internationally, Quest Diagnostics has operations in India, Ireland, and Mexico, and its products and services are used by customers in over 130 countries and on six continents. Their Nichols Institute Worldwide performs specialized testing for clients in more than 50 countries across North America, South America, Europe, Asia, and Australia. The company is actively expanding its sales and reach through health plan collaborations and outreach acquisitions in new geographies. They are also expanding their consumer health offerings through the Apple Health app, which will be available to iPhone and iPad users in the U.S.
How Key Themes May Help/Hurt: Quest Diagnostics is a core player in the "MedTech Long '26: Diagnostics & Early Detection" theme. The accelerating breakthroughs in multiomics, liquid biopsy, and AI computational pathology directly benefit Quest by enhancing the sensitivity and clinical utility of their advanced diagnostic assays, expanding their offerings from late-stage therapy selection into early-stage recurrence tracking and population screening. The demographic aging and rising chronic disease incidence create non-cyclical demand for non-invasive, proactive screening, systematically shifting institutional healthcare spending toward early intervention and preventative diagnostic testing, which Quest is capitalizing on with tests like AD-Detect and its consumer health initiatives. Expanding regulatory and policy frameworks, such as potential PAMA reform via the RESULTS Act and Medicare coverage pathways for new tests, could reduce commercial friction and institutionalize reimbursement for their next-generation assays. The integration with Apple Health app for biomarkers and biometrics aligns perfectly with the broader industry trend of leveraging AI and consumer engagement for proactive health management. While generally beneficial, the theme also presents challenges. Rigorous evidentiary hurdles and lengthy prospective interventional trial mandates for novel assays demand substantial sustained R&D and commercial burn, extending cash-flow break-even horizons. Escalating competitive crowding across liquid biopsy and clinical oncology channels drives up sales acquisition costs and risks pricing erosion as well-capitalized incumbents scale competing molecular test menus. Persistent reimbursement friction, delayed MolDx coverage determinations, and potential CLFS rate adjustments (like the PAMA cuts) create average selling price volatility, compressing testing margins and delaying revenue capture for novel assays. The significant upfront expenses for transformation initiatives like Project Nova also reflect the investment required to stay competitive in this evolving landscape.

3 Main Long-Term Bull Details

Leadership in Advanced Diagnostics and Innovation: Quest Diagnostics is driving significant growth through its innovative advanced diagnostic solutions, particularly in high-growth areas like brain health (e.g., AD-Detect blood test for Alzheimer's, with the addition of Roche p-tau217 test) and oncology. New collaborations, such as with Waters Corporation for the Onclarity self-collection kit for HPV, further expand their offerings in women's health. The ability to combine biometrics with biomarkers through partnerships like Apple Health app is expected to unlock additional insights and drive demand for preventative health.
Operational Excellence and AI/Automation Integration: The company's focus on operational excellence through its Invigorate program is on track to deliver 3% in annual cost savings and productivity improvements. Continued investment in AI and automation, including automated aliquoting solutions in labs and using AI for dialysis water testing, is enhancing efficiency, quality, and patient experience across the business, contributing to margin expansion.
Strategic Collaborations and Consumer Health Expansion: Quest is successfully expanding its market reach and revenue through strategic collaborations with elite healthcare organizations (e.g., Co-Lab Solutions with Corewell Health, Fresenius Medical Care for kidney care, and recent outreach acquisitions). The consumer health channel, including questhealth.com and the new Apple Health app integration, continues to generate robust revenue growth (exceeding 30% for the full year), diversifying revenue streams and strengthening market presence.

3 Main Long-Term Bear Details

Persistent Reimbursement Pressures and Regulatory Uncertainty (PAMA): Ongoing reimbursement pressures and regulatory uncertainty, particularly regarding PAMA data collection and the resulting preliminary rate cuts for 2027, pose a significant risk. Despite efforts to advance the bipartisan RESULTS Act to permanently reform PAMA, its passage remains uncertain, and the estimated 1% revenue impact for 2027 represents a material headwind.
Execution Risks with Large-Scale Transformation Projects and Macroeconomic Headwinds: Large-scale transformation initiatives like Project Nova involve significant upfront expenses, with approximately 70% of the full-year 2026 spend anticipated in the second half and additional investments planned for 2027. Operating margins are also impacted by elevated fuel costs and wage increases, partially offsetting productivity gains.
Intensifying Competition and Business Mix Impact on Revenue per Requisition: The diagnostics market remains highly competitive, with pricing pressures evident in some segments. The business mix from new collaborations like Corewell Health and Fresenius Medical Care, while driving volume, has led to a decrease in total revenue per requisition (down 4.2% in Q3 2026) due to a greater proportion of routine tests, indicating potential margin dilution from certain high-volume partnerships.

Competitors And Differentiation: Quest Diagnostics operates in a highly competitive diagnostics market. Key competitors include other large reference laboratories like Labcorp (LH), as well as specialized diagnostic companies such as Thermo Fisher Scientific, Foundation Medicine, and Sonic Healthcare, and hospital outreach programs. Quest differentiates itself through its broad test portfolio, including innovative advanced diagnostics in areas like advanced cardiometabolic and endocrine, autoimmune, brain health (e.g., Alzheimer's disease testing with Roche p-tau217), oncology, and women's and reproductive health (e.g., Onclarity self-collection kit). They also emphasize operational excellence driven by automation and AI (Invigorate program, automated aliquoting, AI for water testing), strategic collaborations with health systems (Co-Lab Solutions with Corewell Health, Fresenius Medical Care), and a growing consumer health channel (questhealth.com, Apple Health app integration) that focuses on preventative health and wellness. The company also advocates for PAMA reform through the RESULTS Act to ensure fair market-based reimbursement.
Recent Performance & What The Market'S Focused On: Quest Diagnostics delivered a strong third quarter 2026, with consolidated revenues up 10% year-over-year to $3.1 billion and adjusted earnings per share increasing over 15.4% to $3.00. Diagnostic information services revenue grew 10.2%, with organic growth of 10.1%, driven by strength across physician, hospital, and consumer channels. Total volume increased 14.5% year-over-year, with organic volume up 14.4%. The company raised its full-year 2026 guidance for revenues to $12.065 billion-$12.105 billion (9.3%-9.7% growth) and adjusted EPS to $11.25-$11.35. The market is primarily focused on the potential impact of the PAMA rate-setting process for 2027, with an estimated 1% revenue headwind, and the progress of the RESULTS Act in Congress to mitigate these cuts. Investors are also tracking the continued strong organic volume growth (5% ex-Corewell and Fresenius), the margin accretion from consumer health, the operational efficiencies gained from AI and automation (Invigorate program), and the expenses associated with Project Nova. The uptake and material impact of new partnerships, such as the Apple Health app integration and kidney care initiatives, are also key areas of focus.

Revenue Segments And Estimated Mix: {"segments":[{"segment_name":"Consolidated Revenues","estimated_mix":"100%","source_or_comment":"Q3 2026 earnings call","yoy_or_trend_comment":"Up 10% YoY; full year 2026 guidance raised to $12.065B-$12.105B (9.3%-9.7% growth)."},{"segment_name":"Diagnostic Information Services","estimated_mix":"97.9%","source_or_comment":"Q3 2026 earnings call, Q2 FY2026 CSIMarket","yoy_or_trend_comment":"Up 10.2% YoY; 10.1% organic growth."產業: 0, 5, 26},{"segment_name":"Physician Channel","estimated_mix":"71% of 2025 revenues","source_or_comment":"Q3 2026 earnings call","yoy_or_trend_comment":"High single-digit revenue growth."產業: 0, 1, 17, 20, 26},{"segment_name":"Hospital Channel","estimated_mix":"18% of 2025 revenues","source_or_comment":"Q3 2026 earnings call","yoy_or_trend_comment":"Double-digit revenue growth, primarily from Co-Lab Solutions with Corewell Health."產業: 0, 1, 17, 20, 26},{"segment_name":"Consumer Health Channel (questhealth.com and partnerships)","estimated_mix":"9% of 2025 revenues (other diagnostic information services); growing rapidly","source_or_comment":"Q3 2026 earnings call","yoy_or_trend_comment":"Robust revenue growth; expected to exceed 30% for the full year."產業: 0, 1, 5, 17, 26},{"segment_name":"Advanced Diagnostics (across 5 key clinical areas)","estimated_mix":"38% of 2025 revenues (gene-based and esoteric testing); growing portion of testing volume","source_or_comment":"Q3 2026 earnings call","yoy_or_trend_comment":"Double-digit revenue growth for key tests across several areas (e.g., advanced cardiometabolic, hormone, Alzheimer's disease)."產業: 0, 26}]}
Product Brands: questhealth.com
AD-Detect
Haystack MRD
MyQuest app
Quest AI Companion
Elite health profile
Lp(a) test
ApoB test
IntelliDraw
Hologic Genius digital diagnostic system
Roche p-tau217 test
Onclarity self-collection kit
Quanum Lab Services Manager

Bull / Bear Details

Quest Diagnostics maintains a bullish outlook as of October 22, 2026, driven by robust Q3 2026 revenue and adjusted EPS growth, leading to raised full-year guid

Thesis

Quest Diagnostics maintains a bullish outlook as of October 22, 2026, driven by robust Q3 2026 revenue and adjusted EPS growth, leading to raised full-year guidance. Strong performance across physician, hospital, and consumer channels, including the new Apple Health integration, reinforces market leadership. Strategic collaborations, expanding AI-driven operational efficiencies, and innovative diagnostics like Alzheimer's tests enhance its resilient growth trajectory, despite PAMA reimbursement pressures and Project Nova expenses.

Bull case

Quest Diagnostics delivered robust Q3 2026 financial performance, with revenues up 10% and adjusted EPS growing over 15%, leading to a second raise in full-year guidance. This strong organic growth is broad-based across physician, hospital, and consumer channels, demonstrating sustained demand for its solutions and effective market execution, fulfilling expanding clinical care needs.
Innovation in advanced diagnostics and consumer health is a key growth driver. The Apple Health app integration, allowing users to order over 50 biomarkers and combine with biometrics, is expected to fuel the consumer channel's 30%+ growth, which also boasts accretive margins. Expansion in kidney diagnostics, including new partnerships and a specialized sales force, further broadens market reach.
Operational excellence, driven by the Invigorate program, continues to deliver 3% in annual cost savings and productivity improvements, supported by AI and automation in labs. Strategic collaborations, such as the Corewell Health partnership and recent acquisition of outreach assets, along with the Project Nova digital transformation, enhance efficiency, market presence, and future growth.

Bear case

Persistent reimbursement pressures from PAMA remain a significant concern, with the company deeply troubled by flawed data collection (76.5% from independent labs) leading to excessive preliminary 2027 rate cuts. The estimated 1% revenue impact for 2027, and cumulative <1.3% through 2029, poses a material headwind, despite advocacy for the RESULTS Act.
Execution risks from large-scale transformation initiatives like Project Nova involve increasing upfront expenses, with 70% of 2026 spend in H2 and additional investments planned for 2027. Furthermore, the significant growth contribution from Corewell and Fresenius partnerships will be lapped in Q4 2026, removing a key growth factor for 2027.
The diagnostics market remains competitive, with pricing pressures evident in some segments. Elevated fuel costs, projected at $14 million for 2026, continue to impact operating margins. Additionally, a recent cybersecurity incident involving unauthorized access to a test ordering system, while not materially disruptive yet, introduces new operational risk.

Bull / Bear Case

Bear Case: Persistent reimbursement pressures from PAMA remain a significant concern, with flawed data collection leading to excessive preliminary 2027 rate cuts. The estimated 1% revenue impact for 2027 (approximately $120 million) and cumulative <1.3% through 2029 poses a material headwind, with uncertainty surrounding the passage of the RESULTS Act and the company's ability to fully offset these cuts. Execution risks from large-scale transformation initiatives like Project Nova involve increasing upfront expenses, with additional investments planned for 2027. Furthermore, the significant growth contribution from Corewell and Fresenius partnerships will be lapped in Q4 2026, removing a key growth factor for 2027. Elevated fuel costs and wage increases continue to impact operating margins, and a recent cybersecurity incident introduces new operational risk.
Bull Case: Quest Diagnostics delivered robust Q3 2026 financial performance, with revenues up 10% and adjusted EPS growing over 15%, leading to a second raise in full-year guidance. This strong organic growth is broad-based across physician, hospital, and consumer channels, demonstrating sustained demand for its solutions and effective market execution. Innovation in advanced diagnostics, such as the AD-Detect blood test for Alzheimer's and the Apple Health app integration for consumer health, is a key growth driver, with the consumer channel expected to exceed 30% growth with accretive margins. Operational excellence, driven by the Invigorate program, continues to deliver 3% in annual cost savings and productivity improvements, supported by AI and automation in labs. Strategic collaborations and acquisitions further enhance market presence and efficiency.
More Compelling & Why: Bear. Despite strong Q3 results and raised guidance, the stock underperformed the SPY post-earnings, suggesting the market is keenly focused on future headwinds. The estimated 1% revenue impact from PAMA in 2027 (approximately $120 million) is a concrete headwind, and while management plans offsets, the specific amount remains undefined, introducing significant uncertainty into 2027 guidance. This, combined with the lapping of major growth drivers (Corewell/Fresenius) and increasing Project Nova expenses, suggests potential margin pressure and decelerating growth not fully reflected in a P/E ratio that is in line with historical averages. My view would flip if the RESULTS Act passes, effectively mitigating PAMA cuts, and the company provides clear, quantifiable offsets for the remaining impact, demonstrating resilient 2027 EPS growth.

Key Factors5 rows

Key Factor	Why It Matters	What To Watch	What It Signals	Where/How To Track	Free Alt Data	Paid Alt Data
Apple Health App Integration Full Launch and Adoption	The full launch of Quest Diagnostics' lab ordering integration with the Apple Health app represents a significant expansion in the consumer health channel, enabling direct access to over 50 biomarkers and biometric measurements. This partnership could drive robust volume growth and accretive margins.	Monitor for the official announcement of the full launch of the Apple Health app integration, expected later in 2026. Track initial user adoption rates, the volume of lab panels ordered through the app, and any commentary on revenue contribution in subsequent earnings calls.	A successful full launch by year-end 2026 with strong initial uptake and positive management commentary on volume and margin accretion would be a bullish signal. Delays in launch or lower-than-expected adoption rates would be a bearish signal.	Company press releases, Quest Diagnostics' investor relations website, and Apple's official announcements. Future earnings calls will likely provide updates on performance metrics.	1. Google Trends — Search Interest Not in registry Metric/field Search term volume for 'Quest Diagnostics Apple Health' and 'Apple Health lab order' Cadence Weekly Why it matters Indicates public interest and awareness of the new service, potentially correlating with early adoption. Signal to watch Sustained or increasing search interest post-launch = bullish. Declining or low interest = bearish.	1. Sensor Tower / App Annie — App Download & Usage Data Matched (medium)sensor_tower_mobile_app_downloads_usage · access=file · map_only Metric/field Downloads and active users of the Apple Health app (if granular data on Quest integration is available) Cadence Monthly Why it matters Provides insights into the overall engagement with the Apple Health platform, which is a prerequisite for Quest's service adoption. Signal to watch Increased engagement with the Apple Health app post-launch = bullish. Stagnant or declining engagement = bearish.
Project Nova Epic Solutions Deployment Progress	Project Nova, Quest Diagnostics' multi-year initiative to deploy Epic Solutions in its labs, is a significant digital transformation aimed at enhancing provider and patient experiences, improving quality, and driving productivity. Successful deployment is crucial for long-term operational efficiency and growth.	Monitor for updates on the deployment of Epic Solutions in Quest's first lab, which is scheduled for the fall of 2027. Watch for any commentary on the project's timeline, budget adherence, and initial benefits realization.	Deployment of Epic Solutions in the first lab on schedule (fall 2027) and positive commentary on progress and anticipated efficiencies would be a bullish signal. Any delays, cost overruns, or challenges in integration would be a bearish signal.	Quest Diagnostics' earnings calls, investor presentations, and SEC filings (e.g., 10-K, 10-Q).	[]	1. Pintel.AI — Digital Transformation Intelligence Not in registry Metric/field Project Nova implementation progress, integration challenges, and workflow efficiency improvements Cadence Quarterly/Ad-hoc Why it matters Provides detailed insights into the execution and potential pitfalls of the Project Nova initiative, which is a major operational undertaking. Signal to watch Smooth integration and reported efficiency gains = bullish. Stalling workflows or data synchronization issues = bearish.
2027 Full-Year Guidance and PAMA Offset Strategy	Quest Diagnostics will provide its full-year 2027 guidance early next year. This guidance, especially the details on how the company plans to offset the anticipated 1% PAMA revenue headwind, will be crucial for investor confidence and future earnings projections.	Look for the release of Quest Diagnostics' full-year 2027 revenue and EPS guidance, typically provided with Q4 and full-year 2026 earnings results early next year. Pay close attention to management's specific strategies and quantified offsets for the PAMA impact.	Guidance that demonstrates a clear and effective strategy to offset a significant portion of the PAMA impact, leading to a resilient or growing EPS outlook for 2027, would be a bullish signal. If the PAMA impact is largely unmitigated or results in a significant reduction in 2027 EPS guidance, it would be a bearish signal.	Quest Diagnostics' Q4 2026 earnings press release and conference call, expected early next year. The 2027 Investor Day on March 25, 2027, may also provide further details.	[]	[]
Haystack MRD MolDx Medicare Advantage Reimbursement	Securing MolDx Medicare Advantage reimbursement for the Haystack MRD test is vital for expanding its commercial reach and driving revenue growth in the oncology diagnostics segment. This reimbursement would de-risk the test and increase its adoption among eligible patients.	Monitor for an announcement from Quest Diagnostics regarding MolDx Medicare Advantage coverage for Haystack MRD. This was hoped for in the second half of 2026.	If MolDx Medicare Advantage reimbursement is received in H2 2026 or early 2027, it would be a bullish signal, indicating broader market access and revenue potential. If delayed or denied, it would be a bearish signal.	Quest Diagnostics' press releases, SEC filings, and investor relations updates. Industry news from MolDx or CMS may also provide information.	1. CMS.gov — MolDx Local Coverage Determinations (LCDs) Not in registry Metric/field Publication of an LCD for Haystack MRD under MolDx Medicare Advantage Cadence Ad-hoc Why it matters Directly indicates whether Medicare Advantage plans under MolDx will cover Haystack MRD, impacting market access. Signal to watch Publication of a positive LCD = bullish. No publication or negative LCD = bearish.	1. IQVIA / Symphony Health — Medical Claims Data Matchediqvia_medical_claims · access=file · map_only Metric/field CPT code utilization for Haystack MRD (if specific codes are available and trackable) Cadence Monthly Why it matters Provides granular, independent data on actual test utilization and reimbursement trends for Haystack MRD. Signal to watch Increasing claims volume and favorable reimbursement rates = bullish. Stagnant or declining claims, or unfavorable reimbursement = bearish.
PAMA RESULTS Act Legislative Progress and CBO Score	The passage of the RESULTS Act is critical for Quest Diagnostics as it aims to reform the flawed PAMA data collection process, which currently leads to excessive Medicare reimbursement rate cuts. Favorable legislation would stabilize future revenues and profitability.	Investors should monitor for the Congressional Budget Office (CBO) score of the RESULTS Act, expected in mid-to-late November 2026. Also, watch for any announcements regarding the inclusion of the RESULTS Act in an end-of-year legislative package.	A CBO score by mid-November and subsequent inclusion of the RESULTS Act in an end-of-year package, leading to permanent PAMA reform or another delay in cuts, would be a bullish signal. If the RESULTS Act stalls or significant rate cuts (estimated at 1% of total company revenues for 2027, or ~$120M) are implemented without sufficient offsets, it would be a bearish signal.	Updates will likely be available through Quest Diagnostics' investor relations releases, SEC filings (10-K, 10-Q, 8-K), and industry news from organizations like the American Clinical Laboratory Association (ACLA). Congressional news outlets and government websites will also provide information on legislative progress.	1. Congress.gov — Legislative Status Not in registry Metric/field Status of the RESULTS Act (e.g., committee passage, floor vote, CBO score release) Cadence Daily/Weekly Why it matters Directly tracks the legislative progress of the RESULTS Act, which is crucial for PAMA reform and Quest's reimbursement rates. Signal to watch Passage through committees, CBO score release, or inclusion in a year-end package = bullish. Stalling or failure to pass = bearish.	[]

Key Reported Metrics, Reratings Triggers & Results6 rows

This channel is experiencing robust growth, driven by initiatives like the Apple Health app integration, and contributes accretive margins. Its continued strong

Last reported · 2026-10-22

Key reported metrics			Rerating thresholds			Earnings results
Metric	Last period	Why it matters	What's needed for rerating	Rerating context	Earnings date	Actual reported	Hit target?	Notes
Consumer Health Channel Revenue Growth	>30%	This channel is experiencing robust growth, driven by initiatives like the Apple Health app integration, and contributes accretive margins. Its continued strong performance is vital for diversifying revenue and future expansion.
Adjusted EPS Growth	$3.00 (15.4% y/y growth)	Adjusted EPS is a key indicator of Quest Diagnostics' overall profitability and shareholder value. Strong growth signals effective cost management and leverage from revenue growth, driving investor returns.	For Quest Diagnostics (DGX) to rerate higher, the Adjusted Diluted EPS for Q3 2026 needs to hit at least $3.00. This would represent a beat of approximately 5% or more over the current analyst consensus estimates, which range from $2.83 to $2.87. Additionally, another upward revision to the full-year 2026 adjusted EPS guidance (currently $11.05-$11.25) would be a strong catalyst.	Exceeding Adjusted Diluted EPS expectations by a significant margin and raising full-year guidance would reinforce Quest Diagnostics' bullish investment thesis, driven by strong demand for innovative diagnostics and operational efficiencies. It would signal sustained profitability and effective management of cost pressures, enhancing investor confidence in its competitive position and future growth trajectory.	2026-10-22	$3.00 (15.4% y/y growth)	Yes	Quest Diagnostics reported an Adjusted Diluted EPS of $3.00 for Q3 2026, meeting the rerating threshold. This represented a 15.4% increase year-over-year. The company also raised its full-year 2026 adjusted EPS guidance to a range of $11.25-$11.35, up from the previous guidance of $11.05-$11.25. This strong performance and upward revision contributed to a positive outlook.
Consolidated Organic Revenue Growth	$3.1 billion (10.1% organic y/y growth)	This metric indicates the underlying health and demand for Quest Diagnostics' core services, excluding acquisitions. Strong organic growth signals effective strategy execution and market share expansion, crucial for investor confidence.	Consolidated Organic Revenue Growth of 10.5% or higher for Q3 2026.	This metric is crucial as it demonstrates the underlying demand for Quest's core services and the success of its strategic growth initiatives, particularly in advanced diagnostics and consumer health. Exceeding the previous quarter's strong performance and analyst expectations would signal sustained market leadership and effective execution, justifying a higher valuation.	2026-10-22	$3.1 billion (10.1% organic y/y growth)	No	Quest Diagnostics reported consolidated organic revenue growth of 10.1% for Q3 2026. While this was a robust growth rate, it fell slightly short of the rerating trigger of 10.5% or higher. Despite this, management emphasized that their robust organic revenue growth demonstrates their solutions are fulfilling expanding clinical care needs. Total consolidated revenues were $3.1 billion, representing a 10% year-over-year increase.
Revenue per Requisition (adjusted for business mix)	2.9%	This metric indicates the underlying pricing power and mix shift towards higher-value tests, excluding the impact of new, lower-margin collaborations. Its growth suggests increased test complexity and success in advanced diagnostics and consumer health.
Adjusted Diluted EPS	19.1%	Adjusted Diluted EPS is a key indicator of Quest Diagnostics' profitability and operational efficiency. Strong growth signals effective cost management, leverage from revenue growth, and ultimately, enhanced shareholder value.	For Quest Diagnostics (DGX) to rerate higher, the Adjusted Diluted EPS for Q3 2026 needs to hit at least $3.00. This would represent a beat of approximately 5% or more over the current analyst consensus estimates, which range from $2.83 to $2.87. Additionally, another upward revision to the full-year 2026 adjusted EPS guidance (currently $11.05-$11.25) would be a strong catalyst.	Exceeding Adjusted Diluted EPS expectations by a significant margin and raising full-year guidance would reinforce Quest Diagnostics' bullish investment thesis, driven by strong demand for innovative diagnostics and operational efficiencies. It would signal sustained profitability and effective management of cost pressures, enhancing investor confidence in its competitive position and future growth trajectory.	2026-10-22	$3.00 (15.4% y/y growth)	Yes	Quest Diagnostics reported an Adjusted Diluted EPS of $3.00 for Q3 2026, meeting the rerating threshold. This represented a 15.4% increase year-over-year. The company also raised its full-year 2026 adjusted EPS guidance to a range of $11.25-$11.35, up from the previous guidance of $11.05-$11.25. This strong performance and upward revision contributed to a positive outlook.
Consolidated Revenues	10.2%	Consolidated Revenues reflect the overall top-line performance and market demand for Quest Diagnostics' services. Strong growth indicates successful execution of strategy and expanding market share, which is crucial for investor confidence.

Key Questions

Given the estimated 1% revenue impact from PAMA in 2027 and the expected CBO score for the RESULTS Act by mid-November, will Quest Diagnostics successfully advo

Given the estimated 1% revenue impact from PAMA in 2027 and the expected CBO score for the RESULTS Act by mid-November, will Quest Diagnostics successfully advocate for PAMA reform or effectively offset the anticipated reimbursement cuts, and what will be the specific financial impact on 2027 guidance?

Question 2: Can Quest Diagnostics sustain its strong organic revenue growth and volume trends, particularly in its consumer health channel with the full launch of the Apple Health app integration, and will these growth drivers continue to expand operating margins despite ongoing Project Nova investments and elevated fuel costs?
Question 3: Will Quest Diagnostics' strategic collaborations, including the continued margin improvement from Corewell Health and Fresenius Medical Care partnerships and the successful integration of newly acquired outreach assets, continue to drive accretive growth and offset potential business mix impacts on revenue per requisition?

Earnings Transcript Summary3 rows

2026-10-22 · 2026Q3 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Strategic Execution and Growth: Management emphasized strong performance across physician, hospital, and consumer channels, complemented by productivity gains from automation and AI, and highlighted the strategy to connect people and providers to innovative testing and actionable insights. 2. Operational Excellence and Technology Adoption (AI/Automation): The company is focused on delivering 3% in annual cost savings and productivity improvements through its Invigorate program, with automation and AI being major drivers of quality and efficiency improvements, such as automated aliquoting and AI for water testing. 3. Advocacy for PAMA Reform (RESULTS Act): Management is deeply concerned about flawed PAMA data collection and excessive preliminary rate cuts for 2027, actively advocating for the passage of the bipartisan, bicameral RESULTS Act to permanently reform PAMA.	Call Takeaway & ToneThe overall takeaway from the call is highly positive, reflecting Quest Diagnostics' strong financial performance in the third quarter of 2026, with robust revenue and earnings growth driven by sustained demand across physician, hospital, and consumer channels, and enhanced by productivity gains from AI and automation. Management raised full-year guidance for both revenues and EPS, signaling continued momentum. The tone was optimistic and confident regarding business execution and growth strategies, while also being determined and proactive in addressing challenges like PAMA reimbursement pressures through legislative advocacy and internal efficiency initiatives.	Prior Quarter'S Y/Y Growth By SegmentConsolidated revenues: up 10.2% year-over-year. Consolidated organic revenues: up 10% year-over-year. Diagnostic Information Services: up 10.3% year-over-year. Diagnostic Information Services organic growth: 10.1% year-over-year. Physician channel: high single-digit revenue growth. Hospital channel: double-digit revenue growth. Consumer health channel (questhealth.com): robust revenue growth. Advanced diagnostics (across 5 key clinical areas): double-digit revenue growth across several areas.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. PAMA Impact and Offsets: Analysts questioned the potential PAMA headwind for 2027 and how much could be offset. Management stated the PAMA impact is estimated at approximately 1% of total company revenues for 2027, and they intend to offset a portion of this through efficiencies in infrastructure and support functions, without impacting growth drivers or frontline operations. 2. Underlying Organic Volume Growth (ex-Corewell/Fresenius): Analysts inquired about the drivers of the 5% volume growth (excluding Corewell and Fresenius) and how it tracks above market stats. Management responded that this growth was strong across all channels: physician (above mid-single digits revenue growth), hospital reference (double-digit volumes), and consumer (north of 30% growth for the full year). 3. Apple Health Partnership and Consumer Channel: Analysts asked about the expected ramp of the Apple Health partnership, its nuances, materiality, and the pricing environment in the consumer-directed business. Management indicated the partnership is in beta testing, expected to launch later this year, and while a forecast isn't available, it's a great partnership for combining biometrics with biomarkers. They also noted that consumer business margins are accretive due to no denials/concessions and dense requisitions.	Revenue SegmentsConsolidated revenues: up 10% year-over-year. Diagnostic Information Services: up 10.2% year-over-year (10.1% organically). Physician channel: high single-digit revenue growth. Hospital channel: double-digit revenue growth (reference testing revenues grew mid-single digits). Consumer health channel: robust growth, expected to exceed 30% for the full year. Advanced diagnostics (key clinical areas): double-digit revenue growth for key tests.

2026-07-23 · 2026Q2 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Strategic Execution and Growth: Management emphasized 'focused execution of our strategy to connect people and providers to innovative testing and actionable insights', highlighting broad clinical demand, new customer wins, and increased volume from collaborations like Corewell Health and Fresenius Medical Care. They are also focused on expanding advanced diagnostics in key clinical areas such as brain health, oncology (Haystack MRD), and cardiometabolic tests. 2. Operational Excellence and Technology Adoption: A key focus is on driving continuous improvements in quality and productivity through the 'Invigorate program' (aiming for 3% annual cost savings) and investing in 'automation and AI' both in and outside labs, including systems like Hologic Genius and tools like IntelliDraw. 3. Expanding Collaborations and Acquisitions: Management is actively pursuing and growing strategic partnerships, citing the success of Co-Lab Solutions with Corewell Health and Fresenius Medical Care, and a new Co-Lab agreement in California, indicating a strong pipeline for future collaborations and acquisitions of hospital outreach and independent labs.	Call Takeaway & ToneThe overall takeaway from the call is highly positive, reflecting strong financial performance in Q2 2026 with robust top and bottom-line growth, leading to a raised full-year guidance for both revenue and adjusted EPS. Management expressed confidence in their strategic execution, driven by broad clinical demand, successful collaborations, and investments in automation and AI. The tone was optimistic, emphasizing continued momentum and strategic focus, despite acknowledging ongoing reimbursement pressures from PAMA and potential increased expenses in the second half of the year.	Prior Quarter'S Y/Y Growth By SegmentConsolidated Revenues: Up 9.2% YoY. Consolidated Organic Revenues: Up 9% YoY. Diagnostic Information Services: Up 9.4% YoY. Physician Channel: High single-digit revenue growth. Hospital Channel: Double-digit revenue growth, majority from Corewell Health. Consumer Channel (questhealth.com and partnerships): Significant revenue growth, questhealth.com with robust double-digit repeat rates, partnerships even stronger double-digit growth. Advanced Diagnostics (across 5 key clinical areas): Double-digit revenue growth across several areas (e.g., brain health, cardiometabolic and endocrine). AD-Detect blood test more than doubled YoY.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Hospital Channel Performance and Deal Pipeline: Analysts questioned the double-digit growth in the hospital channel, the progression of relationships, the building deal pipeline, and concerns about bad debt exposure. Management responded that the total hospital portfolio was up significantly, driven by Corewell Health. They noted mid-single-digit growth in core reference business and Co-Lab same-store sales (excluding Corewell), indicating no slowdown. They also stated that bad debt is not a concern with hospitals or client bills, and the funnel of opportunities for Co-Lab and outreach deals looks good. 2. Impact of ACA/Medicaid Changes: Analysts asked about the 30 basis points headwind from ACA and Medicaid changes and if it was still embedded in guidance. Management confirmed that the 30 basis point impact is still assumed for the full year. They explained that while enrollment is down, the impact on their business is limited because healthier people dropped off, and sicker people remained, leading to fewer requisitions but more tests per requisition, keeping revenue from the exchange relatively flat. 3. PAMA Reimbursement Outcomes and Mitigation Strategies: Analysts inquired about the potential reimbursement outcomes from PAMA and actions to offset future risks. Management outlined three possible outcomes: new rates implemented by CMS after the July 30 data collection, the passage of the RESULTS Act (which they continue to push for due to strong bipartisan support and a belief it's a fairer way to collect data), or another delay if the RESULTS Act doesn't pass, given Congress's acknowledgment of PAMA's flaws.	Revenue SegmentsConsolidated revenues: up 10.2% year-over-year. Consolidated organic revenues: up 10% year-over-year. Diagnostic Information Services: up 10.3% year-over-year. Diagnostic Information Services organic growth: 10.1% year-over-year. Physician channel: high single-digit revenue growth. Hospital channel: double-digit revenue growth. Consumer health channel (questhealth.com): robust revenue growth. Advanced diagnostics (across 5 key clinical areas): double-digit revenue growth across several areas.

2026-04-21 · 2026Q1 Earnings Call

3 Things Management Is Most Focused On	Call Takeaway & Tone	Prior Quarter'S Y/Y Growth By Segment	3 Things Analysts Most Pressed On (And Mgmt Responses)	Revenue Segments
3 Things Management Is Most Focused On1. Delivering innovative solutions and expanding clinical areas: Management highlighted strong demand for clinical innovations, such as the AD-Detect blood test for Alzheimer's disease (which more than doubled year-over-year) and advanced cardiometabolic testing. They also emphasized expansion into new clinical areas like end-stage renal disease and collaborative lab solutions with health systems like Corewell Health. 2. Operational excellence and leveraging AI/automation: The company is focused on improving productivity and quality through its Invigorate program, aiming for 3% annual cost savings. They are stepping up the deployment of AI and automation both in and outside labs, including boosting customer service productivity by 40% with AI and launching the Quest AI Companion for patients. 3. Strategic collaborations and consumer health: Management is actively pursuing and benefiting from collaborations with elite healthcare and consumer health organizations, driving significant revenue growth from questhealth.com and partnerships with wearable companies and wellness brands. They see this convergence of consumer health, wellness, wearables, and AI as having a profound impact on future healthcare.	Call Takeaway & ToneThe overall takeaway of the call was highly positive, reflecting a strong start to the year for Quest Diagnostics. Management reported robust first-quarter performance with significant revenue and EPS growth, driven by broad-based demand for clinical innovations, successful expansion into new clinical areas, and effective collaborations. The tone was confident and optimistic, underscored by the decision to raise full-year revenue and EPS guidance. Key themes included the successful execution of strategic initiatives, the increasing adoption of advanced diagnostics, the benefits of AI and automation in operations, and the growing momentum in the consumer health segment.	Prior Quarter'S Y/Y Growth By SegmentIn Q4 2025, consolidated revenues were up 7.1% year-over-year. Consolidated organic revenues grew by 6.4% year-over-year. Diagnostic Information Services were up 7.3% year-over-year. The physician channel experienced high single-digit organic revenue growth. The hospital channel saw low single-digit growth. The consumer-initiated testing platform, questhealth.com, exceeded a 20% revenue growth rate. Advanced Diagnostics across several clinical areas showed double-digit revenue growth.	3 Things Analysts Most Pressed On (And Mgmt Responses)1. Organic volume dynamics and contributions from key partnerships: Analysts questioned the drivers of strong organic volume growth, particularly the impact of Fresenius Medical Care and Corewell Health. Management responded that organic volume growth was 10.8% (10.9% total), with Fresenius and Corewell contributing about 7%, meaning 3.8% organic volume growth excluding these two. They also clarified that revenue per requisition was down 1.3% overall due to the business mix of these collaborations but up 2.5% excluding their impact, driven by an increase in tests per requisition from advanced diagnostics and consumer business. 2. PAMA (Protecting Access to Medicare Act) and 2027 Medicare rates: Analysts inquired about Quest's preparation for PAMA data submission and expectations for 2027 Medicare rates. Management confirmed readiness to submit data and expressed hope that if all eligible labs submit, the data would show that rates should increase, as previous submissions were skewed by only a few large providers. They also highlighted efforts to advance the RESULTS Act to keep rates as is for 2027. 3. Impact of government fraud, waste, and abuse initiatives (CRUSH RFI) and prior authorizations: Analysts asked about the CMS' CRUSH RFI and its potential impact. Management stated that Quest does not believe it will be impacted, as 7 of the 10 tests driving the majority of increased Medicare lab spending were proprietary tests Quest does not offer, and their participation in the other 3 molecular-based categories was de minimis. They applauded government efforts against fraud but noted that routine and wellness tests, critical for preventative health, were actually down according to the OIG report. Regarding prior authorizations, management stated they would not ask for them, but suggested CMS require accreditation for labs performing higher complexity tests.	Revenue SegmentsConsolidated revenues were up 9.2% year-over-year. Consolidated organic revenues grew by 9% in the quarter. Revenues for Diagnostic Information Services were up 9.4% compared to the prior year. The physician channel delivered high single-digit revenue growth. The hospital channel grew revenues at a double-digit rate. The consumer channel generated significant revenue growth, with questhealth.com featuring robust double-digit customer repeat rates and partnerships showing even stronger double-digit growth. Advanced diagnostics across several key clinical areas (advanced cardiometabolic and endocrine, autoimmune, brain health, oncology, and women's and reproductive health) delivered double-digit revenue growth. The AD-Detect blood test for Alzheimer's disease more than doubled year-over-year. The hospital reference business was up 3%. The Co-Lab business with Corewell Health was up significantly double-digit growth.

Transcript Tidbits4 rows

2026-10-22

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketQuest Diagnostics is expanding its eligible market through collaborations with Fresenius Medical Care, serving new customers with growing kidney diagnostics expertise, and was named the primary national lab provider for pre-dialysis chronic kidney disease testing for a kidney care organization. The company finalized a definitive agreement to acquire select outreach assets from a leading health system in the Northeastern U.S. In consumer health, Quest announced the ability for iPhone and iPad users to order labs directly from the Apple Health app, offering over 50 biomarkers and biometric measurements. The growth rate across consumer health is expected to exceed 30% for the full year. Quest is delivering innovative tests in five key clinical areas, including advanced cardiometabolic and endocrine, autoimmune, brain health, oncology, and women's and reproductive health, with double-digit revenue growth in several of these areas. They will soon add the FDA-cleared Roche p-tau217 test and launched a new AD-Detect panel for Alzheimer's disease. Additionally, Quest formed the first industry collaboration with Waters Corporation to provide access to the Onclarity self-collection kit for HPV cervical cancer screening. A specialized sales force has been fielded to call on nephrologists, opening up new relationships and opportunities.	About CompetitionThe company remains deeply concerned about the flawed data collection process for PAMA, noting that independent labs represented 76.5% of the volume reported, which is a significant overestimation of their market share, while hospital outreach, with substantial share, accounted for less than 10% of the data. This skewed data collection is believed to adversely affect the volume-weighted median calculation for reimbursement rates. Quest Diagnostics is actively advocating for the passage of the bipartisan, bicameral RESULTS Act to permanently reform PAMA and ensure data used to set rates properly reflects the market.	About The Broader IndustryThe industry is experiencing expanding clinical care needs from an aging population and an increasing focus on prevention and wellness. Hospitals continue to face financial, workforce, and other pressures, leading them to seek strategic partners like Quest Diagnostics for solutions. There's a growing interest in preventative health, with consumers increasingly owning their health. Diagnostic innovations are making many diseases highly preventable through early diagnosis, and there's a vision for Alzheimer's to become a preventable disease diagnosed and treated earlier with blood-based tests. Blood testing for Alzheimer's is still in early phases of development. Lab insights play a critical role in the nation's healthcare. Utilization is expected to continue at current strong levels without moderation. The impact from ACA disenrollment has been modest, with healthier individuals dropping off and sicker patients remaining, leading to higher acuity and more tests per requisition, resulting in a minimal revenue loss of about 10 basis points.	Where Things Are HeadedQuest Diagnostics is raising its guidance for revenues and earnings per share for the full year 2026 due to strong performance. The acquisition of select outreach assets from a Northeastern U.S. health system is expected to close later this year. The full launch of the Apple Health app integration for ordering labs is anticipated later this year. The consumer health growth rate is projected to exceed 30% for the full year. The company plans to add significant new biomarkers to its portfolio for earlier Alzheimer's diagnosis and treatment. The Waters innovation for HPV self-collection is expected to be introduced to clinicians, health plans, and consumers next year. Quest remains on track to deliver 3% in annual cost savings and productivity improvements through its Invigorate program, with plans to extend automated aliquoting capabilities to more labs. Project Nova is on schedule to deploy Epic Solutions in its first lab in the fall of 2027. The company is pushing for the passage of the RESULTS Act by year-end to reform PAMA. The PAMA impact for 2027 is estimated at approximately 1% of total company revenues, with a cumulative impact of less than 1.3% for 2027-2029, and Quest intends to offset a portion of this headwind. Full 2027 guidance will be provided early next year, and a long-term outlook will be shared at the 2027 Investor Day on March 25th. Corewell and Fresenius partnerships will be lapped in Q4 2026, so they will not be a growth factor in 2027, though margin improvement from these partnerships is expected. Additional investments in Project Nova are planned for 2027. Pricing, excluding PAMA, is expected to remain flattish with third-party payers.	Updates On ThemeDiagnostics	Broader Themes EmergingThe deep integration of AI and automation is a broader theme, enhancing quality, productivity, and efficiency across operations, including specimen processing and specialized testing like dialysis water analysis. The convergence of biometrics and biomarkers, as seen with the Apple Health app integration, is emerging as a way to unlock greater health insights and drive proactive health management. Digital transformation in healthcare is evident with Project Nova's advancement to deploy Epic Solutions in labs, aiming to enhance experiences for healthcare providers and patients.	Bullish-Leaning Quotes (Short)We grew revenues 10% and adjusted earnings per share over 15% in the quarter on continued strength across our physician, hospital, and consumer channels, complemented by productivity gains from automation and AI. Our robust organic revenue growth demonstrates that our solutions are fulfilling the expanding clinical care needs of an aging population, as well as the increasing number of people focused on prevention and wellness. With these growth trends and our strong performance, we are again raising our guidance for revenues and earnings per share for the full year. Our strong third quarter reflects the critical role lab insights play in our nation's healthcare.	Bearish-Leaning Quotes (Short)We remain deeply concerned that the data collection process this year was also flawed, and the resulting preliminary rate cuts for 2027 are excessive. The PAMA impact for 2027 is estimated at approximately 1% of total company revenues. Operating margin is expected to expand versus the prior year. Fuel costs... for the year to be at the high end of the range that we previously gave, which is equivalent to close to about $10 million.	HiringThe company mentioned that they 'will not impact things that drive growth. We will not impact our front line. We will not impact our lab operations in any way or our ability to serve patients, because utilization has been very strong, and we continue to be very pleased with the utilization that we are seeing.' They also stated, 'we have to keep the frontline physician staffed in order to handle the volume.' Additionally, Quest has 'fielded a specialized sales force to call on nephrologists.'

2026-07-23

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketQuest Diagnostics expanded its reach through collaborations with Corewell Health and Fresenius Medical Care, driving increased volume. The company also formed a new Co-Lab agreement with a nonprofit regional health system in California. The consumer health channel, including questhealth.com, continued robust revenue growth and attracted new partners. Growth was double-digit across several advanced diagnostic areas like cardiometabolic, autoimmune, brain health, and oncology. New York State approved the Haystack MRD test, allowing commercial efforts in all 50 states, and access was extended through Flatiron Health's Onco EMR Molecular Profiling integration platform. Elevance recently added coverage for the pTau 217 Alzheimer's biomarker, and Medicare Advantage offers broad reimbursement for Alzheimer's panels. The hospital reference business saw mid-single-digit revenue growth, indicating a willingness to outsource more tests, and the pipeline for Co-Lab and outreach deals looks good.	About CompetitionRegarding the Haystack MRD test, Quest Diagnostics believes its assay is 'better than some of the competitors that are out there.' In the context of PAMA, the company noted that 'only one other company' has New York State approval for a tumor-informed ctDNA MRD test. The hospital reference business is described as a 'competitive sector' with 'slightly negative' pricing. Quest Diagnostics advocates for the RESULTS Act to address flaws in the original PAMA data collection process, which resulted in a 'very, very biased statistical sample' of market pricing, suggesting a need for a 'better and fair way' to collect data.	About The Broader IndustryHospitals continue to face 'workforce, financial and other pressures.' There is a growing interest and investment in preventative health and wellness, with consumers increasingly 'taking on of their own health and taking charge of their health.' While ACA exchange enrollment is down, the 'healthier people dropped off, the sicker people remained,' leading to fewer requisitions but more tests per requisition and relatively flat revenue from exchanges. The industry is seeing sustained demand driven by 'chronic conditions that continue to exist in this country.' New treatments for late-stage liver disease are poised for additional growth in liver fibrosis testing. The International Alzheimer's conference highlighted the 'widespread perspective of the importance of both biomarkers' (pTau and amyloid beta) for dementia care. Congress has acknowledged that the original PAMA cuts were 'not sustainable' and the process 'did not work as intended.'	Where Things Are HeadedQuest Diagnostics is raising its full-year guidance for 2026, expecting revenues between $11.95 billion and $12.05 billion (8.3% to 9.2% growth) and adjusted EPS between $11.05 and $11.25. The company anticipates continued expansion of its consumer health platform and solutions for partners. Operational excellence initiatives, including the Invigorate program, are on track to deliver 3% in annual cost savings and productivity improvements. AI and automation investments will continue, with plans to extend front-end specimen processing automation to more sites and implement an AI tool at patient service centers this year. The Corewell Health Co-Lab is expected to scale up to a JV and launch early next year. Haystack MRD commercial investments are being paced commensurate with reimbursement, with MolDx Medicare Advantage reimbursement hoped for in the second half of the year. Utilization is expected to remain strong in the second half, though ACA subsidies will have a higher impact, and the company will lap Corewell and Fresenius in Q4. PAMA has three possible outcomes: new rates implemented January 1, 2027, the RESULTS Act passed, or another delay, with Quest continuing to push for the RESULTS Act.	Updates On ThemeDiagnostics	Broader Themes EmergingThe deep integration of AI and automation is a broader theme emerging across the industry, impacting lab operations, customer engagement, and administrative tasks. This is evidenced by Quest's use of AI for Pap test slide scanning, front-end specimen processing, customer engagement tools like IntelliDraw, and an AI tool for tracking and ordering supplies at patient service centers.	Bullish-Leaning Quotes (Short)Our strong performance in the second quarter demonstrates focused execution of our strategy. In the quarter, we grew revenues by over 10%. We also grew adjusted diluted earnings per share by over 19%. We are again raising our guidance for the year. We are seeing no slowdown at all from reference testing coming to Quest Diagnostics. Our core physician business... is getting growth in the high single digits, both volume and revenue. Our Consumer business... is on the high side of that estimate. The utilization has been very strong, and we really are expecting the same tailwind to continue in the second half. Revenue per requisition was very strong in the quarter. Test per req is definitely continuing to improve. Elevance recently added coverage for certain blood-based biomarker tests for Alzheimer's. Brain health portfolio continues to grow at high double-digit rates.	Bearish-Leaning Quotes (Short)Operating income as a percent of revenues was impacted by investments in Project Nova and the lower operating margin rate associated with the ramp of the Corewell Co-Lab business. Operating income was also adversely impacted by higher supplemental deferred compensation expenses. Total revenue per requisition was down 2.8% versus the prior year due to the Corewell and Fresenius business mix. Fuel costs... for the year to be at the high end of the range that we previously gave, which is equivalent to close to about $10 million. Nova expenses in the second half to be about 70% of the full year. It's a competitive sector, and the pricing is slightly negative there. The ACA exchange subsidy expiration... still assuming for the full year that there's a 30 basis point impact on revenue. DSOs are up again both year-over-year and sequentially in the quarter. We don't want to get too far out in front of ourselves [Haystack MRD]... commensurate with reimbursement. Q3, always a wildcard [weather].	HiringQuest Diagnostics welcomed Domini Chokshi as the new Head of Investor Relations, who joined last week, bringing nearly two decades of experience from Merck. Dan Haemmerle, the Vice President of Finance, will assist in her transition after leading the Investor Relations function for the past few months. Wage increases were mentioned as a factor partially offsetting organic revenue growth and impacting operating income.

2026-07-23

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)	Hiring
About Expanding Eligible MarketQuest Diagnostics expanded its reach through collaborations with Corewell Health and Fresenius Medical Care, driving increased volume. The company also formed a new Co-Lab agreement with a nonprofit regional health system in California. The consumer health channel, including questhealth.com, continued robust revenue growth and attracted new partners. Growth was double-digit across several advanced diagnostic areas like cardiometabolic, autoimmune, brain health, and oncology. New York State approved the Haystack MRD test, allowing commercial efforts in all 50 states, and access was extended through Flatiron Health's Onco EMR Molecular Profiling integration platform. Elevance recently added coverage for the pTau 217 Alzheimer's biomarker, and Medicare Advantage offers broad reimbursement for Alzheimer's panels. The hospital reference business saw mid-single-digit revenue growth, indicating a willingness to outsource more tests, and the pipeline for Co-Lab and outreach deals looks good.	About CompetitionRegarding the Haystack MRD test, Quest Diagnostics believes its assay is 'better than some of the competitors that are out there.' In the context of PAMA, the company noted that 'only one other company' has New York State approval for a tumor-informed ctDNA MRD test. The hospital reference business is described as a 'competitive sector' with 'slightly negative' pricing. Quest Diagnostics advocates for the RESULTS Act to address flaws in the original PAMA data collection process, which resulted in a 'very, very biased statistical sample' of market pricing, suggesting a need for a 'better and fair way' to collect data.	About The Broader IndustryHospitals continue to face 'workforce, financial and other pressures.' There is a growing interest and investment in preventative health and wellness, with consumers increasingly 'taking on of their own health and taking charge of their health.' While ACA exchange enrollment is down, the 'healthier people dropped off, the sicker people remained,' leading to fewer requisitions but more tests per requisition and relatively flat revenue from exchanges. The industry is seeing sustained demand driven by 'chronic conditions that continue to exist in this country.' New treatments for late-stage liver disease are poised for additional growth in liver fibrosis testing. The International Alzheimer's conference highlighted the 'widespread perspective of the importance of both biomarkers' (pTau and amyloid beta) for dementia care. Congress has acknowledged that the original PAMA cuts were 'not sustainable' and the process 'did not work as intended.'	Where Things Are HeadedQuest Diagnostics is raising its full-year guidance for 2026, expecting revenues between $11.95 billion and $12.05 billion (8.3% to 9.2% growth) and adjusted EPS between $11.05 and $11.25. The company anticipates continued expansion of its consumer health platform and solutions for partners. Operational excellence initiatives, including the Invigorate program, are on track to deliver 3% in annual cost savings and productivity improvements. AI and automation investments will continue, with plans to extend front-end specimen processing automation to more sites and implement an AI tool at patient service centers this year. The Corewell Health Co-Lab is expected to scale up to a JV and launch early next year. Haystack MRD commercial investments are being paced commensurate with reimbursement, with MolDx Medicare Advantage reimbursement hoped for in the second half of the year. Utilization is expected to remain strong in the second half, though ACA subsidies will have a higher impact, and the company will lap Corewell and Fresenius in Q4. PAMA has three possible outcomes: new rates implemented January 1, 2027, the RESULTS Act passed, or another delay, with Quest continuing to push for the RESULTS Act.	Updates On ThemeDiagnostics	Broader Themes EmergingThe deep integration of AI and automation is a broader theme emerging across the industry, impacting lab operations, customer engagement, and administrative tasks. This is evidenced by Quest's use of AI for Pap test slide scanning, front-end specimen processing, customer engagement tools like IntelliDraw, and an AI tool for tracking and ordering supplies at patient service centers.	Bullish-Leaning Quotes (Short)Our strong performance in the second quarter demonstrates focused execution of our strategy. In the quarter, we grew revenues by over 10%. We also grew adjusted diluted earnings per share by over 19%. We are again raising our guidance for the year. We are seeing no slowdown at all from reference testing coming to Quest Diagnostics. Brain health portfolio continues to grow at high double-digit rates.	Bearish-Leaning Quotes (Short)Operating income as a percent of revenues was impacted by investments in Project Nova and the lower operating margin rate associated with the ramp of the Corewell Co-Lab business. Operating income was also adversely impacted by higher supplemental deferred compensation expenses. Total revenue per requisition was down 2.8% versus the prior year due to the Corewell and Fresenius business mix. Fuel costs... for the year to be at the high end of the range that we previously gave, which is equivalent to close to about $10 million. Nova expenses in the second half to be about 70% of the full year. It's a competitive sector, and the pricing is slightly negative there. The ACA exchange subsidy expiration... still assuming for the full year that there's a 30 basis point impact on revenue. DSOs are up again both year-over-year and sequentially in the quarter. Q3, always a wildcard [weather].	HiringQuest Diagnostics welcomed [ Domini Chokshi ] as their new Head of Investor Relations, who joined last week. Dan Haemmerle will continue to work closely with [ Dominique ] as she transitions into this new role, following the completion of the hiring reprocess.

2026-04-21

About Expanding Eligible Market	About Competition	About The Broader Industry	Where Things Are Headed	Updates On Theme	Broader Themes Emerging	Bullish-Leaning Quotes (Short)	Bearish-Leaning Quotes (Short)
About Expanding Eligible MarketQuest Diagnostics is expanding into new clinical areas such as end-stage renal disease, serving thousands of dialysis clinics operated by Fresenius Medical Care nationwide and adding independent dialysis clinics. The company is also growing its collaborative lab solutions (Co-Lab) with health systems like Corewell Health, with a strong pipeline for future collaborations and acquisitions. In the consumer channel, significant revenue growth is driven by questhealth.com and partnerships with consumer health organizations, including wearable companies. Advanced diagnostics are a key focus across five clinical areas: advanced cardiometabolic and endocrine, autoimmune, brain health, oncology, and women's and reproductive health, with double-digit revenue growth in several of these. The AD-Detect blood test for Alzheimer's disease more than doubled year-over-year. New guidelines from the American Heart Association recommend Lp(a) and ApoB testing for the first time and recommend screening for high cholesterol at young ages, expanding the eligible patient population. A research collaboration with City of Hope is studying the Haystack MRD test for solid tumor cancers across 14 U.S. sites. The partnership with Guardant for the Shield colon cancer CRC test is also expanding Quest's offerings.	About CompetitionQuest Diagnostics notes that in the PAMA data submission process, historically, only two companies (including Quest and its nearest competitor) submitted over 80% of the data, despite having at best 17% to 20% share of the Medicare market, which could lead to inaccurate rate assessments. The company also highlights that many health plans pay health system labs 200% to 300% of what they pay leading independent labs for outreach work, which penalizes patients and employers. Quest advocates for health plans to pay all labs the same amount for outreach work.	About The Broader IndustryThe broader industry is seeing a significant shift towards advanced diagnostics and early detection, with physicians becoming more confident using blood tests for diagnosis and treatment decisions, often in lieu of imaging, particularly for conditions like Alzheimer's. New clinical guidelines, such as those from the American Heart Association for Lp(a) and ApoB testing and early cholesterol screening, are driving demand for specific biomarkers. There's a strong industry trend towards leveraging AI and automation for productivity gains, both within labs and in customer service operations. The government is increasing efforts to combat fraud, waste, and abuse in healthcare, as evidenced by the CMS' CRUSH RFI, which noted a 5% increase in Medicare lab spending driven by 10 specific tests (7 proprietary to individual labs, 3 molecular-based); however, routine and wellness tests, critical for preventative health, were actually down. There is an emerging convergence of consumer health, wellness, wearables, and AI, which is expected to profoundly impact how people manage their healthcare, leading to a future where pre-doctor visit data (wearable, lab work) is fed into AI for personalized reports and more informed discussions with physicians. This linkage between biomarkers and biometrics, supported by AI, is making people more conscious of their health and likely increasing longitudinal testing.	Where Things Are HeadedQuest Diagnostics is raising its full-year revenue and EPS guidance for 2026, expecting revenues between $11.78 billion and $11.9 billion (6.8% to 7.8% growth) and adjusted EPS in the range of $10.63 to $10.83. Operating margin is expected to expand. The company plans to open a state-of-the-art lab in Southeast Michigan next year as part of its joint venture with Corewell Health. Quest anticipates remaining a leading source of diagnostic innovation for managing diseases like Alzheimer's. The Invigorate program is expected to continue delivering 3% in annual cost savings and productivity improvements. Project Nova, a multiyear initiative to transform order-to-cash processes, is on track for its first wave of solutions in fall 2027. Organic utilization and revenue per requisition (excluding key partnerships) are expected to remain strong. The company anticipates some negative weather impact in the second half of the year and elevated fuel costs. Project Nova expenses are expected to be higher in the second half of the year. The company maintains an assumption of a 30 basis point impact to revenues from ACA disenrollments, though not observed in Q1. Quest is hopeful the RESULTS Act will pass to keep PAMA rates as is for 2027, or that broader data submission will lead to a price increase. The company will continue to pursue other partnerships in consumer health and wellness, and 60-70% of AI/automation efforts will remain focused on laboratory operations.	Updates On ThemeDiagnostics	Broader Themes EmergingThe convergence of consumer health, wellness, wearables, and artificial intelligence is emerging as a profound trend that will reshape healthcare. This includes the 'physical of the future,' where wearable data and lab results are analyzed by AI before a doctor's visit, informing a more focused discussion between patient and physician. The linkage between biometrics (from wearables) and biomarkers (from lab tests), enhanced by AI, is highlighted as incredibly important for proactive health management and is expected to increase longitudinal testing by consumers.	Bullish-Leaning Quotes (Short)Our strong first quarter performance reflects a focused business, delivering innovative solutions. We grew revenues over 9%, almost entirely from organic revenue growth. We grew adjusted diluted earnings per share by approximately 13%, supported by productivity gains from our deployment of automation and AI. We are raising our revenue and EPS guidance for the year. Our pipeline of potential Co-Lab collaborations as well as potential outreach and independent acquisitions remain strong. Our Alzheimer's book of testing more than doubled year-over-year. We expect to continue to deliver 3% in annual cost savings and productivity improvements. We boosted productivity by 40% in the first quarter among customer service agents that used AI. Patients have engaged Quest AI Companion approximately 350,000 times. The M&A funnel is good. The margin on these deals is on par, if not slightly better than our overall enterprise average.	Bearish-Leaning Quotes (Short)The business mix from these 2 collaborations [Fresenius and Corewell] includes a greater proportion of routine tests... total revenue per requisition, which was down 1.3%. Cash from operations was lower than a year ago due to the timing of operating receipts and disbursements and higher bonus payments. We are expecting in the second half of the year this year that we're going to have some negative weather. Fuel costs will continue to be elevated somewhere at the $4 per gallon and above, impacting the next 3 quarters. We have built in, in our guide still the expectation that we do see a 30 basis point impact to revenues as a result of ACA disenrollments. There's a lot to get done before the end of this year [for RESULTS Act], especially with summer vacations and elections coming up. Routine and wellness tests that are critical to preventative health and wellness... those test categories were actually down.

NotesTable

Date	Comment	Comment Type	Comment Sentiment	Link	Price Reaction
2026-10-22	Quest Diagnostics reported strong Q3 2026 results with 10% revenue and over 15% adjusted EPS growth, raising full-year guidance. Management highlighted broad demand, AI-driven efficiencies, and advancing consumer health via Apple Health integration. Despite PAMA reimbursement concerns (1% 2027 revenue impact), the market reacted positively, with DGX outperforming SPY by 1.05% (t+2 days), signaling confidence in its growth trajectory and mitigation strategies.	Earnings Transcript	Neutral		+1.24% (vs SPY: +1.05%)

Upcoming Events9 rows

Catalyst ID	Estimated Timing	Estimated Date Start	Estimated Date End	Catalyst	Why It Matters	Ticker Or Theme Specific	Transcript Date	Source Type
DGX_bb8518fe	effective January 1, 2027	2027-01-01	2027-01-01	Final 2027 Clinical Laboratory Fee Schedule (CLFS) rates become effective.	This legislative outcome will directly influence Medicare reimbursement rates for a wide range of diagnostic tests, affecting the profitability and market access for Quest Diagnostics and the broader diagnostics sector.	Theme	2026-07-23	earnings_transcript
DGX_1aec303d	early next year	2027-01-01	2027-03-31	Launch of the Corewell Health joint venture (JV) and a new lab in Michigan.	This JV is a significant strategic collaboration for Quest Diagnostics, expected to contribute positively to revenues and potentially improve operating margins over time.	Ticker	2026-07-23	earnings_transcript
DGX_cfca96b5	by mid-November	2026-11-01	2026-11-15	Congressional Budget Office (CBO) scoring of the bipartisan, bicameral RESULTS Act.	A CBO score is a crucial milestone for the RESULTS Act, which aims to permanently reform PAMA and ensure fair Medicare reimbursement rates for diagnostic labs. A favorable score could increase the likelihood of its inclusion in year-end legislation, mitigating potential revenue cuts from PAMA.	Theme	2026-10-22	earnings_transcript
DGX_ae4871f6	early next year	2027-01-01	2027-03-31	Launch of a state-of-the-art lab in Southeast Michigan as part of the joint venture with Corewell Health.	This joint venture is a significant growth driver for Quest's hospital channel, contributing to volume growth and expanding collaborative lab solutions.	Ticker	2026-04-21	earnings_transcript
DGX_104d8516	next year	2027-01-01	2027-03-31	Introduction of the Waters Corporation's Onclarity self-collection kit for HPV testing through Quest Diagnostics' clinical, health plan, and consumer health channels.	This collaboration expands Quest's women's health portfolio with a new, convenient at-home option for cervical cancer screening, potentially driving volume and revenue in the consumer health and clinical channels.	Ticker	2026-10-22	earnings_transcript
DGX_c0c7190c	early next year	2027-01-01	2027-03-31	Quest Diagnostics anticipates scaling up its Corewell Health Co-Lab relationship to a joint venture and launching a new lab in Michigan.	This represents a significant expansion of a strategic partnership, expected to contribute positively to revenues and strengthen Quest's presence in the hospital channel.	Ticker	2026-07-23	earnings_transcript
DGX_af31e761	by year's end	2026-11-16	2026-12-31	Potential passage and enactment of the RESULTS Act as part of a year-end legislative package.	The passage of the RESULTS Act would permanently reform PAMA, potentially preventing excessive rate cuts for diagnostic services in 2027 and beyond, which would be a significant positive for Quest Diagnostics and the industry.	Theme	2026-10-22	earnings_transcript
DGX_89bf1d10	later this year	2026-10-01	2026-12-31	Full launch of Quest Diagnostics' lab ordering and results service directly through the Apple Health app for iPhone and iPad users.	This partnership is expected to drive robust growth in the consumer health channel by making lab testing more accessible and integrated with personal health data, potentially unlocking greater health insights and increasing utilization.	Ticker	2026-10-22	earnings_transcript
DGX_b3b059a5	later this year	2026-10-01	2026-12-31	Rollout of Haystack MRD through Flatiron Health's Onco EMR Molecular Profiling integration platform to Flatiron's 4,700 clinicians and other providers nationwide.	This integration provides ease of ordering and tracking for Haystack MRD, potentially driving increased adoption and volume for Quest Diagnostics' oncology test.	Ticker	2026-07-23	earnings_transcript

Prior Earnings Metrics HistoryTable

Prior earnings scorecards

Key Inputs And Sourcing

1. Labor (Wages)

2. Reagents and Consumables

3. Logistics and Fuel

4. Diagnostic Equipment and Automation

5. IT and Software (Project Nova, AI)

6. Specimen Collection Kits and Packaging

7. Utilities (Electricity, Water)

8. Rent and Leases (Labs, PSCs)

9. Medical Waste Disposal

Industry Publications

Economic Data Watch

1. FRED — Personal Consumption Expenditures

2. FRED — Employment Cost Index

3. FRED — Crude Oil Prices

4. FRED — Real Personal Consumption Expenditures

5. FRED — Consumer Price Index

Free Alt Data Watch

1. ClinicalTrials.gov — Clinical Trial Registry

2. FDA — Medical Device 510(k) Clearances and Premarket Approvals (PMA)

3. SEC EDGAR — Company Filings

4. Google Trends — Search Interest

5. USPTO PatentsView — Patent Grants and Applications

Paid Alt Data Watch

1. IQVIA / Symphony Health — Medical Claims Data

2. Definitive Healthcare — PhysicianView / ClaimsMx

3. Truveta — EHR Data

4. Consumer Edge — Healthcare Claims Data (Phoenix/Hydrus)

5. LegiScan — U.S. Legislative Database

Search Keywords Brand Product

Search Keywords Event Phrases

Search Keywords Policy Regulatory

3 Main Long-Term Bull Details

3 Main Long-Term Bear Details

Thesis

Bull case

Bear case

1. Google Trends — Search Interest

1. Sensor Tower / App Annie — App Download & Usage Data

1. Pintel.AI — Digital Transformation Intelligence

1. CMS.gov — MolDx Local Coverage Determinations (LCDs)

1. IQVIA / Symphony Health — Medical Claims Data

1. Congress.gov — Legislative Status

Last reported · 2026-10-22